Electrocardiographic alterations in patients consuming synthetic cannabinoids

Abstract

Introduction:

The aim of this study was to investigate the electrocardiographic parameters in patients consuming synthetic cannabinoids.

Methods:

Thirty-five patients who were consuming synthetic cannabinoids were enrolled to the study, prospectively. The control group included 35 healthy age and sex-matched volunteers. The standard 12-lead surface electrocardiograms of the study population were recorded. P maximum (P_max), P minimum (P_min), P wave dispersion, interatrial duration, P wave area in D2 derivation, abnormal P terminal force in V1 derivation, heart rate, QT interval, corrected QT, QT dispersion, PR interval duration and macrovolt T-wave alternans were evaluated by two experienced cardiologists. The intra-observer and inter-observer variations for all measurements were non-significant.

Results:

P_max and P_min duration was not different between the groups (p=0.96, p=0.15, respectively). However, P wave dispersion was higher in the patient group compared to control group (34±9.4, 29.5±6.6, p=0.02, respectively). QT interval was significantly higher in the patient group than the control group (380.3±25, 365.6±22.8, p=0.01, respectively). Besides, corrected QT was higher in the patient group compared to control group (415±36.8, 392±15.5, p=0.001, respectively). QT dispersion was also higher in the patient group than the control group (39.8±10.0, 29.2±5.4, p<0.001, respectively).

Conclusion:

Altered electrocardiography parameters linked with atrial and ventricular arrhythmia development may be observed in patients consuming synthetic cannabinoids. These patients should be evaluated regularly for cardiovascular disease and arrhythmia development. The electrocardiogram, which is a cheap and easy test to apply, can be used to determine the pro-arrythmic risk in patients consuming synthetic cannabinoids.

Keywords

Synthetic cannabinoid electrocardiography cardiovascular system arrhythmia

Get full access to this article

View all access options for this article.

References

Acciavatti

Martinotti

Corbo

et al . (2017) Psychotropic drugs and ventricular repolarisation: The effects on QT interval, T-peak to T-end interval and QT dispersion. J Psychopharmacol 31: 453–460.

Akcay

Acar

Suner

et al . (2009) Effects of slow coronary artery flow on P-wave dispersion and atrial electromechanical coupling. J Electrocardiol 42: 328–333.

Al Kury

Voitychuk

Yang

et al . (2014) Effects of the endogenous cannabinoid anandamide on voltage-dependent sodium and calcium channels in rat ventricular myocytes. Br J Pharmacol 171: 3485–3498.

Aro

Anttonen

Kerola

et al . (2014) Prognostic significance of prolonged PR interval in the general population. Eur Heart J 35: 123–129.

Atik

Dedeoglu

Varol

et al . (2015) Cardiovascular side effects related with use of synthetic cannabinoids “bonzai”: Two case reports. Turk Pediatri Ars 50: 61–64.

Aydin Sunbul

Sunbul

Terzi

et al . (2016) The effect of synthetic cannabinoids on P-wave dispersion: An observational study. Med Princ Pract 25: 483–487.

Brents

Prather

(2014) The K2/Spice phenomenon: Emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products. Drug Metab Rev 46: 72–85.

Castaneto

Gorelick

Desrosiers

et al . (2014) Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend 144: 12–41.

Cooper

(2016) Adverse effects of synthetic cannabinoids: Management of acute toxicity and withdrawal. Curr Psychiatry Rep 18: 52.

10.

Davis

Boddington

(2015) Teenage cardiac arrest following abuse of synthetic cannabis. Heart Lung Circ 24: e162–e163.

11.

Dilaveris

Batchvarov

Gialafos

et al . (1999) Comparison of different methods for manual P wave duration measurement in 12-lead electrocardiograms. Pacing Clin Electrophysiol 22: 1532–1538.

12.

Dilaveris

Gialafos

Andrikopoulos

et al . (2000) Clinical and electrocardiographic predictors of recurrent atrial fibrillation. Pacing Clin Electrophysiol 23: 352–358.

13.

Dilaveris

Gialafos

Sideris

et al . (1998) Simple electrocardiographic markers for the prediction of paroxysmal idiopathic atrial fibrillation. Am Heart J 135: 733–738.

14.

Efe

Felekoglu

Cimen

et al . (2017) Atrial fibrillation following synthetic cannabinoid abuse. Turk Kardiyol Dern Ars 45: 362–364.

15.

Elbey

Oylumlu

Akil

et al . (2012) Relation of interatrial duration and p wave terminal force as a novel indicator of severe mitral regurgitation. Eur Rev Med Pharmacol Sci 16: 1576–1581.

16.

Evans-Brown

Gallegos

Francis

et al . (2015) New Psychoactive Substances in Europe: An Update from the EU Early Warning System. Lisbon: EMCDDA.

17.

Ford

Tai

Fantegrossi

et al . (2017) Synthetic pot: Not your grandfather’s marijuana. Trends Pharmacol Sci 38: 257–276.

18.

Ghuran

Nolan

(2000) Recreational drug misuse: Issues for the cardiologist. Heart 83: 627–633.

19.

Jimenez-Candil

Hernandez Hernandez

Aguero

et al . (2009) Early reduction of QT dispersion after primary percutaneous intervention in ST-segment elevation acute myocardial infarction. Mechanisms and clinical implications. Cardiology 113: 172–179.

20.

Jin

Weisse

Hernandez

et al . (1988) Significance of electrocardiographic isolated abnormal terminal P-wave force (left atrial abnormality): An echocardiographic and clinical correlation. Arch Intern Med 148: 1545–1549.

21.

Krylatov

Maslov

Ermakov

et al . (2007) Significance of cardiac cannabinoid receptors in regulation of cardiac rhythm, myocardial contractility, and electrophysiologic processes in heart. Izv Akad Nauk Ser Biol 1: 35–44.

22.

Lamy

Daniulaityte

Nahhas

et al . (2017) Increases in synthetic cannabinoids-related harms: Results from a longitudinal web-based content analysis. Int J Drug Policy 44: 121–129.

23.

Lindsay

Foale

Warren

et al . (2005) Cannabis as a precipitant of cardiovascular emergencies. Int J Cardiol 104: 230–232.

24.

Malik

Batchvarov

(2000) Measurement, interpretation and clinical potential of QT dispersion. J Am Coll Cardiol 36: 1749–1766.

25.

Martinotti

Cinosi

Santacroce

et al . (2017a) Substance-related psychopathology and aggressiveness in a nightlife holiday resort: Results from a pilot study in a psychiatric inpatient unit in Ibiza. Hum Psychopharmacol 32. doi: 10.1002/hup.2586.

26.

Martinotti

Santacroce

Papanti

et al . (2017b) Synthetic cannabinoids: Psychopharmacology, clinical aspects, and psy-chotic onset. CNS Neurol Disord Drug Targets 16: 567–575.

27.

Maslov

Ermakov

Lasukova

et al . (2006) Paticipation of cannabinoid receptors in the regulation of cardiac rhythm and cardiac contractility. Ross Fiziol Zh Im I M Sechenova 92: 429–439.

28.

Mills

Yepes

Nugent

(2015) Synthetic cannabinoids. Am J Med Sci 350: 59–62.

29.

Narayan

(2006) T-wave alternans and the susceptibility to ventricular arrhythmias. J Am Coll Cardiol 47: 269–281.

30.

Nose

Bighelli

Castellazzi

et al . (2016) Prevalence and correlates of QTc prolongation in Italian psychiatric care: Cross-sectional multicentre study. Epidemiol Psychiatr Sci 25: 532–540.

31.

Shafi

Gallagher

Stewart

et al . (2017) The risk of violence associated with novel psychoactive substance misuse in patients presenting to acute mental health services. Hum Psychopharmacol 32. doi: 10.1002/hup.2606.

32.

Shah

Garg

Patel

et al . (2016) Can your heart handle the spice: A case of acute myocardial infarction and left ventricular apical thrombus. Int J Cardiol 215: 129–131.

33.

Tournebize

Gibaja

Kahn

(2016) Acute effects of synthetic cannabinoids: Update 2015. Subst Abus 38: 344–366.

34.

Von Der Haar

Talebi

Ghobadi

et al . (2016) Synthetic cannabinoids and their effects on the cardiovascular system. J Emerg Med 50: 258–262.

35.

Weinsaft

Kochav

Kim

et al . (2014) P wave area for quantitative electrocardiographic assessment of left atrial remodeling. PLoS One 9: e99178.

36.

Westin

Frost

Brede

et al . (2016) Sudden cardiac death following use of the synthetic cannabinoid MDMB-CHMICA. J Anal Toxicol 40: 86–87.

37.

Yilmaz

Demirbag

(2005) P-wave dispersion in patients with stable coronary artery disease and its relationship with severity of the disease. J Electrocardiol 38: 279–284.

38.

Yilmaz

Unal

Kuyumcu

et al . (2015) Acute anterior myocardial infarction after “Bonzai” use. Anatol J Cardiol 15: 265–266.

39.

Yun

Yoon

Lee

T-H

et al . (2016) Synthetic cannabinoid, JWH-030, induces QT prolongation through hERG channel inhibition. Toxicol Res 5: 1663–1671.

40.

Zeng

Wei

Zhao

et al . (2003) Electrocardiographic diagnosis of left atrial enlargement in patients with mitral stenosis: The value of the P-wave area. Acta Cardiol 58: 139–141.

41.

Zubrzycki

Liebold

Janecka

et al . (2014) A new face of endocannabinoids in pharmacotherapy. Part I: Protective role of endocannabinoids in hypertension and myocardial infarction. J Physiol Pharmacol 65: 171–181.